BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33785875)

  • 1. Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer.
    Semaan A; Bernard V; Kim DU; Lee JJ; Huang J; Kamyabi N; Stephens BM; Qiao W; Varadhachary GR; Katz MH; Shen Y; San Lucas FA; Gascoyne P; Alvarez HA; Maitra A; Guerrero PA
    Br J Cancer; 2021 Jun; 124(12):1970-1977. PubMed ID: 33785875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CTC phenotyping for a preoperative assessment of tumor metastasis and overall survival of pancreatic ductal adenocarcinoma patients.
    Sun Y; Wu G; Cheng KS; Chen A; Neoh KH; Chen S; Tang Z; Lee PF; Dai M; Han RPS
    EBioMedicine; 2019 Aug; 46():133-149. PubMed ID: 31375425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutations in pancreatic circulating tumor cells: a pilot study.
    Kulemann B; Liss AS; Warshaw AL; Seifert S; Bronsert P; Glatz T; Pitman MB; Hoeppner J
    Tumour Biol; 2016 Jun; 37(6):7547-54. PubMed ID: 26684803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumour cells as a biomarker for diagnosis and staging in pancreatic cancer.
    Ankeny JS; Court CM; Hou S; Li Q; Song M; Wu D; Chen JF; Lee T; Lin M; Sho S; Rochefort MM; Girgis MD; Yao J; Wainberg ZA; Muthusamy VR; Watson RR; Donahue TR; Hines OJ; Reber HA; Graeber TG; Tseng HR; Tomlinson JS
    Br J Cancer; 2016 Jun; 114(12):1367-75. PubMed ID: 27300108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer.
    Court CM; Ankeny JS; Sho S; Winograd P; Hou S; Song M; Wainberg ZA; Girgis MD; Graeber TG; Agopian VG; Tseng HR; Tomlinson JS
    Ann Surg Oncol; 2018 Apr; 25(4):1000-1008. PubMed ID: 29442211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EVALUATING MMP-2 AND TGFß-RI EXPRESSION IN CIRCULATING TUMOR CELLS OF PANCREATIC CANCER PATIENTS AND THEIR CORRELATION WITH CLINICAL EVOLUTION.
    Gasparini-Junior JL; Fanelli MF; Abdallah EA; Chinen LTD
    Arq Bras Cir Dig; 2019; 32(2):e1433. PubMed ID: 31038558
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer.
    Riva F; Dronov OI; Khomenko DI; Huguet F; Louvet C; Mariani P; Stern MH; Lantz O; Proudhon C; Pierga JY; Bidard FC
    Mol Oncol; 2016 Mar; 10(3):481-93. PubMed ID: 26856794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epithelial-to-mesenchymal Transition Heterogeneity of Circulating Tumor Cells and Their Correlation With MDSCs and Tregs in HER2-negative Metastatic Breast Cancer Patients.
    Papadaki MA; Aggouraki D; Vetsika EK; Xenidis N; Kallergi G; Kotsakis A; Georgoulias V
    Anticancer Res; 2021 Feb; 41(2):661-670. PubMed ID: 33517270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma.
    Vicente D; Lee AJ; Hall CS; Lucci A; Lee JE; Kim MP; Katz MHG; Hurd MW; Maitra A; Rhim Md AD; Tzeng CD
    J Surg Res; 2019 Nov; 243():90-99. PubMed ID: 31170555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sergeant G; Roskams T; van Pelt J; Houtmeyers F; Aerts R; Topal B
    BMC Cancer; 2011 Jan; 11():47. PubMed ID: 21281486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of circulating tumor cells in patients with ampullary cancer.
    Sun B; Liu H; Wang S; Xiang J; Liu X
    J Cell Physiol; 2018 Jun; 233(6):5014-5022. PubMed ID: 29215725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumour cells as an indicator of early and systemic recurrence after surgical resection in pancreatic ductal adenocarcinoma.
    Park Y; Jun HR; Choi HW; Hwang DW; Lee JH; Song KB; Lee W; Kwon J; Ha SH; Jun E; Kim SC
    Sci Rep; 2021 Jan; 11(1):1644. PubMed ID: 33462311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating Tumor Cells as a Biomarker in Pancreatic Ductal Adenocarcinoma.
    Liu H; Sun B; Wang S; Liu C; Lu Y; Li D; Liu X
    Cell Physiol Biochem; 2017; 42(1):373-382. PubMed ID: 28558380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the Clinical Utility of Pancreatic Cancer Circulating Tumor Cells.
    Yeo D; Bastian A; Strauss H; Saxena P; Grimison P; Rasko JEJ
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery.
    Sergeant G; van Eijsden R; Roskams T; Van Duppen V; Topal B
    BMC Cancer; 2012 Nov; 12():527. PubMed ID: 23157946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
    Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
    Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition.
    Gorges TM; Tinhofer I; Drosch M; Röse L; Zollner TM; Krahn T; von Ahsen O
    BMC Cancer; 2012 May; 12():178. PubMed ID: 22591372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combination of circulating tumor cells and CA199 improves the diagnosis of pancreatic cancer.
    Chen J; Wang H; Zhou L; Liu Z; Tan X
    J Clin Lab Anal; 2022 May; 36(5):e24341. PubMed ID: 35334495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.